Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are emerging as an important therapy to consider for patients with type 2 diabetes (T2D) given the ability of this agent class to reduce glycated haemoglobin and associated weight loss and low risk for hypoglycaemia. Here, GLP1R is linked to type 2 diabetes mellitus.